GlassScriptPhysician profile
John T Berry
NPI 1417319690
$13,090.63
in general payments reported to CMS, 2019-2025
11 companies · $12K in 2025
The $12K reported for 2025 was more than what 91% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $176 · 2023: $286 · 2024: $651 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $1,618 · Travel and Lodging: $1,272 · Education: $13.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,012.50 |
| Food and Beverage | $1,617.51 |
| Travel and Lodging | $1,271.61 |
| Education | $13.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $11,718.89 | 2022-2025 | |
| Abbvie INC. | $509.79 | 2022-2025 | |
| Janssen Biotech, INC. | $322.52 | 2022-2025 | Tremfya, Simponi Aria |
| Glaxosmithkline, LLC. | $125.06 | 2025 | Benlysta |
| Amgen INC. | $124.68 | 2023 | Evenity |
| Genentech USA, INC. | $115.91 | 2024-2025 | Actemra |
| Janssen Scientific Affairs, LLC | $91.75 | 2025 | Tremfya |
| Sandoz INC. | $31.21 | 2025 | Jubbonti |
| E.R. Squibb & Sons, L.L.C. | $21.00 | 2025 | Orencia |
| Ucb, INC. | $16.65 | 2023 | Cimzia |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.